What insurance policy changes affect HCPCS A9579?

There are 7 tracked policy changes affecting HCPCS A9579, including updates from Aetna, Blue Cross Blue Shield of Vermont. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for HCPCS A9579?

Payers that have issued tracked updates for HCPCS A9579 include: Aetna, Blue Cross Blue Shield of Vermont.

How do I get notified when HCPCS A9579 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to HCPCS A9579. You will receive a daily digest email whenever a new policy change references this code.

Why do payers change policies for HCPCS A9579?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

A9579 — Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml: Insurance Policy Changes

A9579 Insurance Policy Changes

HCPCS A9579 is officially defined as "Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml." HCPCS A9579 is referenced in 7 tracked payer policy changes from Aetna and Blue Cross Blue Shield of Vermont. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for HCPCS A9579 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

High impact

Magnetic Resonance Imaging of the Cardiovascular System - Cardiac MRI (CPB 0520, reviewed 2026-08-20)

Aetna·Identified Oct 5, 2026

Aetna has updated its Cardiac MRI policy (CPB 0520) effective immediately, establishing comprehensive medical necessity criteria for cardiac MRI across 13 major clinical indications while designating specific advanced techniques (absolute quantification of myocardial blood flow, 4D flow MRI, whole-heart coronary MRA, ferumoxytol use) as experimental/investigational and not covered. Billing teams must verify that all cardiac MRI claims align with the listed covered indications and prior authorization documentation requirements.

A9579 Insurance Policy Changes

Magnetic Resonance Imaging (MRI) and Computed Tomography (CT) of the Spine (CPB 0236, reviewed 2026-04-09)

Magnetic Resonance Imaging of the Cardiovascular System - Cardiac MRI (CPB 0520, reviewed 2025-08-13)

Magnetic Resonance Imaging of the Cardiovascular System - Cardiac MRI (CPB 0520, reviewed 2026-08-20)

CMO Corner: Supporting Mental Health in Vermont

Endolymphatic Hydrops (Meniere's Disease) Tests (CPB 0571, reviewed 2025-12-02)

Rilonacept (Arcalyst) (CPB 0770, reviewed 2026-09-11)

Endolymphatic Hydrops (Meniere's Disease) Tests (CPB 0571, reviewed 2026-09-01)